This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Learn more here.

DNTH Insider Trading

Insider Ownership Percentage: 11.56%
Insider Buying (Last 12 Months): $1,314,676.05
Insider Selling (Last 12 Months): $0.00

Dianthus Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Dianthus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dianthus Therapeutics Share Price & Price History

Current Price: $24.75
Price Change: Price Increase of +0.65 (2.70%)
As of 02/29/2024 01:00 AM ET

This chart shows the closing price history over time for DNTH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Learn more here.

Dianthus Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/29/2023Fairmount Funds Management LlcDirectorBuy24,670$13.63$336,252.101,928,503View SEC Filing Icon  
9/26/2023Fairmount Funds Management LlcDirectorBuy30,000$13.15$394,500.001,903,833View SEC Filing Icon  
9/21/2023Simrat RandhawaInsiderBuy2,000$13.20$26,400.002,000View SEC Filing Icon  
9/19/2023Fairmount Funds Management LlcDirectorBuy30,000$13.20$396,000.001,873,833View SEC Filing Icon  
9/12/2023Fairmount Funds Management LlcDirectorBuy14,887$10.85$161,523.951,834,466View SEC Filing Icon  
See Full Table
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Learn more here.

SEC Filings (Institutional Ownership Changes) for Dianthus Therapeutics (NASDAQ:DNTH)

47.53% of Dianthus Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at DNTH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Dianthus Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/15/2024Vanguard Group Inc.153,646$1.60M0.0%+21.1%1.037%Search for SEC Filing on Google Icon
2/15/2024Nantahala Capital Management LLC328,433$3.42M0.2%-2.5%2.216%Search for SEC Filing on Google Icon
2/15/2024Octagon Capital Advisors LP554,000$5.76M0.9%+15.4%3.738%Search for SEC Filing on Google Icon
2/14/2024Vestal Point Capital LP135,000$1.40M0.1%N/A0.911%Search for SEC Filing on Google Icon
2/13/2024Northern Trust Corp15,301$0.16M0.0%N/A0.103%Search for SEC Filing on Google Icon
2/13/2024Tower Research Capital LLC TRC 2,430$25K0.0%N/A0.016%Search for SEC Filing on Google Icon
2/7/2024Dimensional Fund Advisors LP14,736$0.15M0.0%N/A0.099%Search for SEC Filing on Google Icon
12/18/2023Vanguard Group Inc.126,877$1.73M0.0%N/A0.856%Search for SEC Filing on Google Icon
12/6/2023Citigroup Inc.3,868$53K0.0%N/A0.026%Search for SEC Filing on Google Icon
11/15/2023Laurion Capital Management LP36,393$0.50M0.0%N/A0.960%Search for SEC Filing on Google Icon
11/14/2023Avidity Partners Management LP1,217,554$16.64M0.7%N/A32.125%Search for SEC Filing on Google Icon
11/13/2023Atlas Venture Life Science Advisors LLC236,979$3.24M0.5%N/A6.249%Search for SEC Filing on Google Icon
11/13/2023Acadian Asset Management LLC22,299$0.30M0.0%N/A0.588%Search for SEC Filing on Google Icon
11/13/2023FMR LLC2,218,212$28.96M0.0%N/A58.497%Search for SEC Filing on Google Icon
11/9/2023Citigroup Inc.3,868$53K0.0%N/A0.102%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Dianthus Therapeutics logo
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Read More on Dianthus Therapeutics

Today's Range

Now: $24.75
Low: $24.01
High: $25.11

50 Day Range

MA: $17.79
Low: $10.13
High: $25.50

52 Week Range

Now: $24.75
Low: $6.58
High: $26.98

Volume

90,581 shs

Average Volume

117,424 shs

Market Capitalization

$366.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

Who are the company insiders with the largest holdings of Dianthus Therapeutics?

Dianthus Therapeutics' top insider investors include:
  1. Fairmount Funds Management Llc (Director)
  2. Simrat Randhawa (Insider)
Learn More about top insider investors at Dianthus Therapeutics.

Who are the major institutional investors of Dianthus Therapeutics?

Dianthus Therapeutics' top institutional shareholders include:
  1. Octagon Capital Advisors LP — 3.74%
  2. Nantahala Capital Management LLC — 2.22%
  3. Vanguard Group Inc. — 1.04%
  4. Vestal Point Capital LP — 0.91%
  5. Northern Trust Corp — 0.10%
  6. Dimensional Fund Advisors LP — 0.10%
Learn More about top institutional investors of Dianthus Therapeutics stock.

Which institutional investors are selling Dianthus Therapeutics stock?

Within the last quarter, DNTH stock was sold by these institutional investors:
  1. Nantahala Capital Management LLC

Which institutional investors are buying Dianthus Therapeutics stock?

In the previous quarter, DNTH stock was bought by institutional investors including:
  1. Vestal Point Capital LP
  2. Octagon Capital Advisors LP
  3. Vanguard Group Inc.
  4. Northern Trust Corp
  5. Dimensional Fund Advisors LP
  6. Tower Research Capital LLC TRC
During the last year, these company insiders have bought Dianthus Therapeutics stock:
  1. Fairmount Funds Management Llc (Director)
  2. Simrat Randhawa (Insider)
Learn More investors buying Dianthus Therapeutics stock.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Full details and steps to take here.